Dr. Garcia Discusses the LATITUDE Study in Prostate Cancer

Partner | Cancer Centers | <b>Cleveland Clinic</b>

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the LATITUDE study in prostate cancer.

This randomized phase III study randomized patients to receive either standard therapy with androgen-deprivation therapy (ADT) with placebo or ADT with abiraterone acetate (Zytiga) and prednisone at 5 mg per day.

Garcia says that LATITUDE has changed the standard of care—adding abiraterone upfront has helped patients live longer, and has reduced the risk of relapse.